VIVAZEN Launches New Botanical Gummy Line: Feel Great™ Function Meets Great Taste
PHOENIX, AZ, April 8, 2025 (EZ Newswire) -- VIVAZEN, the trusted name in functional plant-based supplements, is proud to announce the launch of its all-new Botanical Gummies—a tasty, convenient, and effective way to help support energy, focus, relaxation, and mood. Backed by the same plant-powered benefits Everyday Heroes™ have come to love, the new gummies deliver the feel-good function of VIVAZEN in a chewable format that fits any lifestyle.
Available now at feelgreatbotanics.com, VIVAZEN Botanical Gummies come in three functional options:
Energy + Focus (Berry Bliss): From busy schedules to big goals, stay sharp and energized with this clarity-boosting blend. Whether you're powering through a workout, tackling a big project, or just need to bring your A-game, this berry-awesome gummy delivers the same functional kick as our best-selling Energy + Focus shot—now in a tasty chew.
Stress Relief (Cider Crush): Made with a unique blend of botanicals that may help support your body's natural response to stress. Smooth, crisp, and calming—Stress Relief gummies are your go-to for taking the edge off when the pressure's on.
Relax + Unwind (Citrus Chill): Become a Zen master in 20 minutes. When it's time to shut off the noise and reclaim your calm, Relax + Unwind gummies may help you find your peace and bring it with you anywhere.
All formulas feature botanically active ingredients and are available in great-tasting flavors—no harsh aftertaste, just clean, craveable chews that make it easier than ever to Feel Great™.
'Our customers wanted a way to experience the benefits of VIVAZEN without taking a shot,' said Jerry Barker, VP of Innovation at VIVAZEN. 'With these gummies, we've created something that's tasty, portable, and powerful—a new format that fits seamlessly into your daily routine.'
Why fans are loving VIVAZEN Botanical Gummies:
Great new taste: No more compromise—just flavorful, plant-powered goodness.
Convenient packs: Grab-and-go pouches for on-the-move support.
Three functional options: Choose what you need, when you need it.
Try-all variety pack: The perfect intro for new users or gift for your wellness-curious friends.
Whether you're managing stress at work, gearing up for a workout, or just looking for a better way to balance your day, VIVAZEN Botanical Gummies are your new feel-good ritual—plant-based, purpose-driven, and made for real life.
Disclaimer: VIVAZEN products are not intended to diagnose, treat, cure or prevent any disease and these statements have not been evaluated by the FDA.
About VIVAZEN
VIVAZEN fuels Everyday Heroes™ with the power of plants. For over a decade, we've delivered trusted, high-quality botanical supplements that help people power through, focus up, chill out, and boost their mood—without compromise. Rooted in centuries of herbal wisdom and backed by modern innovation, VIVAZEN is a functional, feel-good alternative for those who want to live—and feel—on their own terms. Join the millions who trust VIVAZEN to Feel Great™, naturally and visit https://feelgreatbotanics.com.
SOURCE: VIVAZEN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
an hour ago
- CNET
The First At-Home Cervical Cancer Screening Wand: Cost, Insurance Coverage and How It Works
Many people dread going into the doctor's office for a Pap smear or HPV test, but that's no longer the only cervical cancer screening option. Now, we have the Teal Wand, the first and only at-home vaginal sample self-collection device for cervical cancer screening in the US. It allows people with a cervix to easily screen themselves for the highly preventable cancer from the comfort of their home. After receiving FDA approval in May, the Teal Wand is now available in California. By 2027, it should be accessible across the US. If you're curious about giving it a try, here's everything you need to know. How the Teal Wand works "The Teal Wand is a self-collection device in which the collected sample is mailed to a lab to test for high-risk HPV using an FDA-approved Primary HPV test," said Kara Egan, Teal Health's CEO and co-founder. The Teal Wand requires a prescription, which you can get through Teal Health on First, you fill out a medical eligibility questionnaire, order a screening kit and schedule a 10-minute virtual visit with a Teal provider. (You can see the OBGYNs and nurse practitioners on Teal's team here.) During the appointment, the provider will review your screening history and discuss the process. After the prescription is approved, a kit will be shipped directly to your home. Collecting your sample at home only takes a few minutes. Print and video instructions can help guide you, and Teal support can answer questions. When you're done, simply package your sample and ship it to a CLIA-certified lab with the materials provided. (CLIA, or Clinical Laboratory Improvement Amendments, are regulations requiring any facility examining human specimens, like tissue, blood and urine, for diagnosis, prevention or treatment purposes, to be certified by the Secretary of the Department of Health and Human Services.) After the lab processes your sample, a Teal provider reviews the results in accordance with the screening guidelines defined by the American Society for Colposcopy and Cervical Pathology (ASCCP). You'll receive results in your secure Teal portal within about a week after sending your sample. You'll be given the opportunity to virtually connect with a Teal provider to discuss any next steps. If follow-up care is needed, the Teal team will coordinate your referral. What the Teal Wand tests for Just like in the clinician's office, your sample is tested for 14 types of high-risk HPV (Human Papillomavirus) that present the highest risk of causing cervical cancer, Egan said. According to the World Health Organization, 99% of cervical cancer cases are linked to HPV infections. Primary HPV tests are the most sensitive tests recommended by the American Cancer Society and the US Preventive Services Task Force for cervical cancer screening. According to Teal Health, the Teal Wand uses the Roche cobas Primary HPV test, which is the same test your doctor would use. Teal's national clinical trial also concluded that "self-collection using the Teal Wand is as accurate as going into the clinic where a provider collects the sample using a speculum and tests for HPV." The Teal Wand is simply a different way of collecting the sample. Teal Health Who can use the Teal Wand? There are three types of cervical cancer tests: Primary HPV testing every five years, Pap tests every three years and co-tests that combine both an HPV test with a Pap test every five years. According to the ASCCP's guidelines, Primary HPV testing through self-collection, which the Teal Wand uses, is suitable for people at average risk for cervical cancer. Teal Health follows the American Cancer Society's guidelines, which recommend HPV testing every five years for people aged 25 to 65 who have an intact cervix. Note that the US Centers for Disease Control and Prevention (CDC) recommends that people between the ages of 30 and 65 get either an HPV test, a Pap test or both as a co-test. (This is different from the American Cancer Society's recommendation, which starts at age 25 instead of 30.) If you're considered at risk of cervical cancer, the CDC recommends that you start getting Pap tests as early as age 21. For those over age 65, consult your doctor. You may not need to be screened anymore if you've received normal or negative results from at least three Pap tests or two HPV tests in the past 10 years, or if you've had your cervix removed during a total hysterectomy for noncancerous conditions like fibroids. Regardless of how, it's important to get screened regularly, even if you've been vaccinated against HPV. If you're not sure which test is right for you, your doctor can help you decide. Who shouldn't use the Teal Wand? Egan said that self-collection with the Teal Wand is not currently recommended for: patients with a history of cancer in the reproductive system patients with HIV (human immunodeficiency virus) patients with DES (diethylstilbestrol, a synthetic form of estrogen) exposure patients with immunosuppression patients who have had a treatment for cervical precancer, such as LEEP (Loop Electrosurgical Excision Procedure) or cold knife cone patients who are pregnant or within six weeks of giving birth Does the Teal Wand replace a Pap smear? The Teal Wand is not the same as a Pap smear (cervical cytology). Instead of in-office, clinician-collected samples with a speculum, like you'd have with a Pap smear, Primary HPV screening allows for self-collected samples. Teal describes a Pap smear as being less sensitive compared to HPV testing because it can only detect cell changes once they've happened, a potential sign that cancer is already present. That's why Pap smears are performed more often than Primary HPV testing (every three years versus five years). On its own, a Pap also doesn't test for HPV, which is the primary cause of almost all cervical cancers. "Universally, a cervical cancer screening is often called a Pap smear, but Pap smear, along with the HPV test, are both types of tests for cervical cancer screening," Egan said. "Screening for HPV using the Teal Wand is an alternative to screening in person." In other words, once you screen using the Teal Wand, you don't need to do the test again in your doctor's office. However, if your results are abnormal and positive for HPV, you may need to get additional in-person testing, such as a colposcopy or a Pap smear, to check for cell changes. Your Teal provider will advise you accordingly, per medical guidelines, based on the HPV type detected and your screening history. While Teal Health aims to help people stay up-to-date on cervical cancer screening, it's always recommended to continue yearly in-person preventive care visits. Teal Health Teal Wand costs and health insurance With select insurance companies, the full at-home screening experience with telehealth consults is available for $99. Without insurance, it's $249, but is eligible for HSA/FSA reimbursement. Teal Health is currently working with the following insurance plans in California: Cigna, Aetna, Anthem Blue Cross, Blue Shield of California and United Healthcare. The company aims to expand its coverage and also provide financial assistance when needed. When will the Teal Wand be available outside California? Teal Health is planning to have the Teal Wand available across the US before the end of 2026. What's the goal with the Teal Wand? According to Egan, Teal Health is on a mission to improve women's healthcare experiences. Teal Health is also a member of the Cervical Cancer Roundtable, a collaboration between the American Cancer Society and the Biden Cancer Moonshot, a coalition of industry leaders working to eliminate cervical cancer as a public health concern in the US. "By creating the option for a woman to screen for cervical cancer from the comfort of home and providing telehealth follow-up, Teal can increase access to this life-saving cancer screening, get more women screened and work toward eliminating cervical cancer in the US, as it is the only cancer nearly 100% preventable with proper screening," said Egan.
Business Upturn
3 hours ago
- Business Upturn
Coloplast A/S – Interim Financial Report, 9M 2024/25
By GlobeNewswire Published on August 19, 2025, 10:33 IST 2024/25 Interim financial results, 9M 2024/25 1 October 2024 – 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT 1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin 1,2 was 28%, against 27% last year. was DKK 1,915 million, a 2% increase from last year. The EBIT margin was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT 1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin 1 was 27%, on par with last year 2 . was DKK 5,718 million, a 4% increase from last year. The EBIT margin was 27%, on par with last year . Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. 'We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here Access the conference call webcast directly here: Coloplast – 9M 2024/25 conference call For further information, please contact Investors and analysts Anders Lonning-SkovgaardExecutive Vice President, CFO Tel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981 Email: [email protected] Press and media Peter MønsterSr. Media Relations ManagerTel. +45 4911 2623 Email: [email protected] Address Coloplast A/SHoltedam 1DK-3050 HumlebaekDenmark Company reg. (CVR) no. 69749917 Website This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_release Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Insider
4 hours ago
- Business Insider
Crinetics' treatment of CAH granted FDA orphan designation
Crinetics (CRNX)' treatment of congenital adrenal hyperplasia, generic name atumelnant, was granted FDA orphan designation, according to a post to the agency's site. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
